+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Secondary Hyperparathyroidism (SHPT) - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762933
  • Report
  • April 2019
  • Region: Global
  • 52 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Amgen Inc
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Novadiol Inc
  • OPKO Health Inc
  • TaiRx Inc
  • MORE
Summary

Secondary Hyperparathyroidism (SHPT) pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Secondary Hyperparathyroidism (SHPT) R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Secondary Hyperparathyroidism (SHPT) report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Secondary Hyperparathyroidism (SHPT) as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Secondary Hyperparathyroidism (SHPT) with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Secondary Hyperparathyroidism (SHPT) pipeline Profiled in detail

Key players actively participating in Secondary Hyperparathyroidism (SHPT) pipeline are profiled along with their R&D progress in Secondary Hyperparathyroidism (SHPT) treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Secondary Hyperparathyroidism (SHPT) pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Secondary Hyperparathyroidism (SHPT) treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Secondary Hyperparathyroidism (SHPT) pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Secondary Hyperparathyroidism (SHPT) pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Secondary Hyperparathyroidism (SHPT) pipeline study
  • All recent news and developments related to Secondary Hyperparathyroidism (SHPT) drugs are provided
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Novadiol Inc
  • OPKO Health Inc
  • TaiRx Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Secondary Hyperparathyroidism (SHPT) Disease Overview

3. Secondary Hyperparathyroidism (SHPT) R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Secondary Hyperparathyroidism (SHPT) Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Secondary Hyperparathyroidism (SHPT) Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Secondary Hyperparathyroidism (SHPT) companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Secondary Hyperparathyroidism (SHPT) Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Amgen Inc
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novadiol Inc
  • OPKO Health Inc
  • TaiRx Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll